

# High-Throughput *In Vitro* ADME Analysis with Agilent RapidFire/MS Systems

A streamlined cytochrome P450 inhibition assay

#### **Author**

Vaughn Miller Agilent Technologies, Inc.

### Introduction


Analysis of cytochrome P450 (CYP) inhibition is an important component of the drug discovery process as adverse drug-drug interactions can lead to termination of a drug development program, withdrawal from the market, or restrictions on therapeutic use. The desire to eliminate weak candidates at earlier phases of the drug discovery process has caused *in vitro* ADME analysis to shift earlier as well, resulting in the need to evaluate a larger number of samples. Therefore, an efficient means of analyzing cytochrome P450 assays in a fast and cost-effective manner is required. Agilent RapidFire/MS systems combine high-throughput sample processing with triple quadrupole (QQQ) or time-of flight (TOF) mass spectrometry (MS) to streamline ADME assay analysis.

### Direct cytochrome P450 inhibition

RapidFire/MS systems have been validated to use FDA-recommended drug probes for cytochrome P450 assays (Table 1). Direct CYP inhibition experiments were performed in the following manner:  $IC_{50}$  values for a range of positive control inhibitors (seven non-zero inhibitor concentrations) were determined in individual incubations of pooled human liver microsomes (HLM) using FDA-preferred or acceptable drug probe substrates with previously validated assay methods. 1 Stably labeled isotope internal standards were used for probe substrate metabolites. Samples were analyzed individually on a RapidFire/MS/MS system and by traditional LC/MS/MS. Correlation of results are shown in Figure 1, and indicate that the RapidFire system produces equivalent results to LC/MS/MS.<sup>2</sup> The RapidFire run time was approximately 6 seconds per sample, compared to 2 to 4 minutes for LC/MS/MS, providing an efficient and productive means to evaluate cytochrome P450 assays within existing laboratory workflows.

**Table 1.** RapidFire/MS systems can analyze FDA-recommended drug probes.

CYP1A2	tacrine, melatonin
CYP2B6	bupropion
CYP2C8	amodiaquol, taxol
CYP2C9	tolbutamide, diclofenac
CYP2C19	S-mephentoin, omeprazole
CYP2D6	dextromethorphan, bufuralol
CYP2E1	chlorzoxazone
CYP3A4/5	midazolam, testosterone, nifedipine, erthromycin



**Figure 1.** Correlation of  $IC_{50}$  values obtained by traditional LC/MS/MS and RapidFire/MS/MS. Data represent eight different enzyme/substrate pairs with one to three inhibitors for each. The dotted line represents a line of unity.

## Time-dependent cytochrome P450 inhibition

Time-dependent CYP inhibition experiments were performed using similar methods. 1 IC<sub>50</sub> values were calculated from seven-point curves for a range of inhibitors using the standard dilution approach, in duplicate individual incubations in HLMs, using FDA-preferred CYP3A4 drug probe substrates (midazolam and testosterone). Correlation of IC<sub>50</sub> results are shown in Figure 2, and again indicate that the RapidFire/MS/MS system produces equivalent results to LC/MS/MS3 while increasing the productivity of assay analysis approximately 20-fold.

### Conclusion

The Agilent RapidFire High-throughput Mass Spectrometry system was used to analyze the cytochrome P450 inhibition assay. RapidFire methods for CYP inhibition have been developed for the standard FDA-approved substrate molecules. The results from two sets of experiments illustrate the key benefits of the RapidFire System compared to conventional LC/MS methods: a greater than 10-fold increase in throughput (6 to 10 seconds processing time per sample), and equivalent inhibition results (IC<sub>50</sub> values). As a result, the RapidFire system significantly increased the efficiency and throughput of conventional laboratory workflows for these assays.

### www.agilent.com/chem/rapidfire

DE.4751851852

This information is subject to change without notice.

Ritonavir/Midazolam RapidFire/MS/MS Ritonavir/Midazolam traditional LC/MS/MS 100 100 - With NAPH With NAPH - Without NADPH Without NADPH remaining activity remaining activity 80 80 60 60 40 40 20 20 0.001 0.01 0.001 0.001 0.01 Inhibitor concentration [µM] Inhibitor concentration [µM] Azamulin/Midazolam RapidFire/MS/MS Azamulin/Midazolam traditional LC/MS/MS → With NADPH - With NAPH 100 remaining activity emaining activity 100 Without NADPH - Without NADPH 80 80 60 60 40 40 20 20 0.001 0.01 0.001 0.01 0.1 0.1 Inhibitor concentration [µM] Inhibitor concentration [µM] Diltiazem/Midazolam RapidFire/MS/MS Diltiazem/Testosterone traditional LC/MS/MS 120 120 → With NAPH Without NAPH Without NADPH - Without NADPH 100 remaining activity remaining activity 100 80 80 60 60 40 40 20 20 1.000 1.000 10 100 10 100 Inhibitor concentration [µM] Inhibitor concentration [uM]

**Figure 2.** A comparison of  $IC_{50}$  values (time-dependent inhibition) for a range of inhibitors, using CYP3A4 drug probe substrates with RapidFire/MS/MS and traditional LC/MS/MS methods, shows equivalent results. However, a full  $IC_{50}$  curve (seven points) can be analyzed with RapidFire/MS/MS in less time than a single LC/MS/MS data point.

### References

- Perloff, E. et al. Validation of Cytochrome P450 Time-Dependent Inhibition Assays: a Two-Time Point IC<sub>50</sub> Shift Approach Facilitates Kinact Assay Design. Xenobiotica 2011, 39(2), 99–112.
- Perloff, E. et al. Comparison of RapidFire Ultra High Throughput LC/MS/MS with Traditional LC/MS/ MS for Cytochrome P450 Inhibition Testing. Abstract #106, Presented at the 11th European ISSX Meeting, May 17–20, 2009, Lisbon, Portugal.
- 3. Miller, V. et al. Evaluation of High Throughput Screening Methods for Time-Dependent Inhibitionof CYP3A4 Utilizing RapidFire LC/MS/MS Technology. Presented at the 11th European ISSX Meeting May 17–20, 2009, Lisbon, Portugal.

